Article Text

NIH Announces 15 Clinical and Translational Science Awards

Statistics from

The National Institutes of Health (NIH) announced more than $79 million in fiscal year 2013 funding to support 15 Institutional Clinical and Translational Science Awards (CTSA). The CTSA program, led by the National Center for Advancing Translational Sciences (NCATS), supports a consortium of more than 60 research institutions across the nation that is focused on bolstering translational research. The institutions receiving the five-year awards are:

  • Albert Einstein College of Medicine, New York City

  • Dartmouth College, Hanover, NH

  • Duke University, Durham, NC

  • Harvard Medical School, Boston

  • Indiana University, Indianapolis

  • Johns Hopkins University, Baltimore

  • Ohio State University, Columbus

  • Scripps Research Institute, La Jolla, CA

  • Stanford University, Stanford, CA

  • Tufts University, Boston

  • University of Colorado, Denver

  • University of North Carolina at Chapel Hill

  • University of Texas Health Science Center, San Antonio

  • University of Texas Southwestern Medical Center, Dallas

  • University of Utah, Salt Lake City

Additional details of these awards and other CTSA institutions can be found online at

NIAID Names New Director of Vaccine Research Center

John R. Mascola, MD, has been named the new director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Dr. Mascola will also serve as chief of the VRC virology laboratory. He previously served as acting director and deputy director of the VRC, and has led the center’s core virology laboratory. He succeeds Gary J. Nabel, MD, PhD, who left the position of VRC Director to become the deputy to the president for Global Research and Development, senior vice president and chief scientific officer at the pharmaceutical company Sanofi in November 2012.

Dr. Mascola’s groundbreaking work has focused on HIV vaccine development. He and colleagues were the first to demonstrate that the infusion of neutralizing antibodies could protect against mucosal HIV exposure in monkeys and have also made promising …

View Full Text

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.